What Is Retatrutide? Viral Weight Loss Drug Claimed to Battle Obesity—But Is It Even Real?

Retatrutide, developed by Eli Lilly, is gaining attention on social media as a new weight-loss medication. It is rumored to be the first medication targeting weight loss through three mechanisms: by influencing GLP-1, GIP hormones, and glucagon receptors. GLP-1 helps control appetite, GIP aids in regulating blood sugar and metabolism, and glucagon increases insulin sensitivity.

However, Retatrutide is still undergoing safety testing and is only in its third phase of development. It has not yet received approval from the U.S. Food and Drug Administration or any other regulatory body, meaning it is not available for public use. Medical trials are ongoing, with participants closely monitored for side effects and given gradual dose increases.

Despite the lack of official approval, influencers on platforms like TikTok and Instagram are promoting what are claimed to be versions of Retatrutide. This has raised concerns, prompting health warnings about the potential dangers of counterfeit products. In response, social media companies are removing videos promoting these unauthorized versions.

Leading medical professionals suggest that even if Retatrutide gains regulatory approval, access to the drug may be limited due to strict eligibility criteria. Approval applications may be submitted as early as mid-to-late 2026, with a potential global launch projected for 2027, though availability in the UK could take longer.